1.
Int Ophthalmol Clin
; 64(1): 179-193, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38146890
2.
Orbit
; 41(4): 525-526, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33349089
3.
Hematol Oncol Clin North Am
; 33(2): 291-299, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30833001
RESUMO
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8+ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.